在帕金森病中,多巴胺激动剂血清度和冲动控制障碍
Sara C Staubo1,2, Ole Martin Fuskevåg3,4,5, Mathias Toft1,6
1Department of Neurology, Oslo University Hospital, Oslo, Norway.
European journal of neurology
|November 13, 2023
概括
帕金森病患者的冲动控制障碍 (ICD) 与较高的罗皮尼罗尔血清度有关,而不是pramipexole. 这凸显了需要对罗皮尼罗尔进行治疗药物监测,以减轻ICD风险.
科学领域:
- 神经学 神经学
- 药理学 药理学是指药理学的学科.
- 精神病学是一个精神病学.
背景情况:
- 冲动控制障碍 (ICD) 是帕金森病患者使用多巴胺激动剂的已知并发症.
- 多巴胺激动剂血清度与ICDs发展之间的关系需要进一步研究.
研究的目的:
- 调查多巴胺激动剂血清度较高是否与帕金森病患者的ICD相关.
- 为了比较血清度和pramipexole和ropinirole的剂量在患有和没有ICD的患者.
主要方法:
- 一项涉及帕金森病患者使用pramipexole或ropinirole的病例控制研究.
- 在帕金森病评分尺度中使用冲动-强迫性障碍问卷对ICD进行查.
- 在剂后多个时间点测量血清药物度,并评估临床数据.
主要成果:
- 与对照人群相比,使用罗皮尼罗尔的ICD患者的血清度 (Cmax) 和每日剂量较高.
- 对于使用普拉米佩克索尔的人来说,血清度或剂量没有发现显著差异.
- 接受罗皮尼罗尔治疗的ICD患者的疾病持续时间和治疗持续时间更长.
结论:
- 普拉米醇的使用可能会独立增加ICD风险,而与罗皮尼罗尔相关的ICD与血清度和药物暴露有关.
- 罗皮尼罗尔的可变的药物动力学特征需要对治疗药物进行监测.
- 监测罗皮尼罗尔血清水平对于降低帕金森病患者内科疾病发病率至关重要.
更多相关视频
06:45Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease
Published on: October 4, 2021
2.8K
11:26Assessment of Dopaminergic Homeostasis in Mice by Use of High-performance Liquid Chromatography Analysis and Synaptosomal Dopamine Uptake
Published on: September 21, 2017
12.5K
相关概念视频
01:24Parkinson's Disease: Treatment
281
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
281
01:15Parkinson's Disease: Overview
564
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
564
01:29Drugs Affecting Neurotransmitter Synthesis
1.4K
Drugs affecting neurotransmitter synthesis can impact the adrenergic neuron and the synthesis of neurotransmitters. For example, α-methyltyrosine and carbidopa target specific enzymes involved in catecholamine synthesis. α-methyltyrosine inhibits the enzyme tyrosine hydroxylase, which converts tyrosine into dopamine. By blocking this enzyme, α-methyltyrosine reduces dopamine production and other catecholamines. Carbidopa, on the other hand, inhibits the enzyme dopa decarboxylase,...
1.4K
01:37Neural Regulation
39.5K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
39.5K
01:28Drugs Affecting GI Tract Motility: Dopamine Receptor Antagonists
348
Prokinetic agents are specialized medications that stimulate gastrointestinal (GI) motility, promoting food movement through the GI tract. Dopamine, an inhibitory neurotransmitter, plays a significant role in this process, reducing GI motility and indirectly controlling the speed of digestion. Dopamine receptor antagonists, such as metoclopramide and domperidone, offer a unique advantage as prokinetic agents. By blocking the dopamine receptors, these drugs increase GI motility, improving food...
348